Keymed Biosciences reported interim results for the six months ended June 30, 2026 with total revenue of RMB617 million. Its core product Kangyueda delivered RMB393 million in sales, up 132% year-over-year, indicating strong momentum in the main franchise.
Keymed Biosciences reported interim results for the six months ended June 30, 2026 with total revenue of RMB617 million. Its core product Kangyueda delivered RMB393 million in sales, up 132% year-over-year, indicating strong momentum in the main franchise.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
